Acetaminophen (APAP) hepatotoxicity-Isn't it time for APAP to go away?

J Hepatol. 2017 Dec;67(6):1324-1331. doi: 10.1016/j.jhep.2017.07.005. Epub 2017 Jul 20.


Acetaminophen (APAP) is the most commonly used drug for the treatment of pain and fever around the world. At the same time, APAP can cause dose-related hepatocellular necrosis, responsible for nearly 500 deaths annually in the United States (US) alone, as well as 100,000 calls to US Poison Control Centers, 50,000 emergency room visits and 10,000 hospitalisations per year. As an over-the-counter and prescription product (with opioids), APAP toxicity dwarfs all other prescription drugs as a cause of acute liver failure in the US and Europe, but it is not regulated in any significant way. In this review the ongoing controversy surrounding the proper role for this ubiquitous pain reliever: its history, pathogenesis, clinical challenges in recognition and management, and current regulatory status are highlighted. A new solution to a 50-year-old problem is proposed.

Keywords: APAP; Acetaminophen; Hepatotoxicity.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Acetaminophen / metabolism
  • Acetaminophen / poisoning
  • Acetaminophen / toxicity*
  • Chemical and Drug Induced Liver Injury / etiology*
  • Drug Overdose
  • Humans
  • Liver Failure, Acute / chemically induced
  • United States
  • United States Food and Drug Administration


  • Acetaminophen